Corrigendum to 'De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel'
In: Annals of Oncology, Jg. 33 (2022-03-01), S. 355-355
Online
unknown
Zugriff:
Titel: |
Corrigendum to 'De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel'
|
---|---|
Autor/in / Beteiligte Person: | Nitz, U.A. ; Gluz, O. ; Christgen, M. ; Grischke, E.-M. ; Augustin, D. ; Kuemmel, S. ; Braun, M. ; Potenberg, J. ; Kohls, A. ; Krauss, K. ; Stefek, A. ; Schumacher, C. ; Forstbauer, H. ; Reimer, T. ; Fischer, H. ; Liedtke, C. ; Wuerstlein, R. ; Schumacher, J. ; Kates, R. ; Kreipe, H. ; Harbeck, N. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 33 (2022-03-01), S. 355-355 |
Veröffentlichung: | Elsevier BV, 2022 |
Medientyp: | unknown |
ISSN: | 0923-7534 (print) |
DOI: | 10.1016/j.annonc.2021.12.008 |
Schlagwort: |
|
Sonstiges: |
|